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Psychological Factors that Interfere with Provider Use of Medication Assisted Treatment
for Opioid Use Disorder

Courtney Spencer
Graduate School of Clinical Psychology
George Fox University
Newberg, Oregon

Abstract

Since the implementation of Medication Assisted Treatment (MAT) for treatment of
Opioid Use Disorder (OUD), providers have struggled to obtain the necessary waiver (X-waiver)
due to required federal applications, training, and guidelines around prescribing. Nevertheless,
prescribers have gone through this arduous process to gain their X-waiver, but a unique
phenomenon has occurred where some providers with an X-waiver are not utilizing their ability
to prescribe MAT. The current study sought to uncover trends in providers prescribing practices
while assessing possible factors involved including personality, compassion, compassion fatigue,
personal connection, and confidence factors that may be associated with a willingness to
prescribe. The study used an electronic survey including the following measures: The
Professional Quality of Life (ProQOL), the Big 5 Inventory-10 (BFI-10), followed by a subset of
additional questions to assess confidence, personal relatability to OUD, and the providers
subjective experience treating patients with MAT. The survey was sent to providers in Oregon
that included X-waivered physicians (Group 1), non-X-waivered nurse practitioners (Group 2),
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and X-waivered physicians in leadership roles (Group 3). Results were analyzed with SPSS.
Results showed moderate effect size correlations between number of patients treated and
connections to colleagues (r = .420), connections to relatives (r = .301) and connection to friends
(r=.32) respectively. Additionally, results showed large effect size correlations between burnout
and confidence in Medication Assisted Treatment (MAT; r = .653), and large correlations
between confidence in provider, patient, and clinic ability and providers’ willingness to
prescribe. Additionally, the study showed that providers working with MAT were likely to have
a higher-level openness and experience a gratifying relationship with patients that drives their
desire to work with this high-risk population.

Keywords: Medication Assisted Treatment (MAT), Opioid Use Disorder (OUD), Xwaiver, DATA 2000 waiver, Compassion Fatigue, Personality, Provider, Confidence.
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Chapter 1
Introduction
Opioid Prescribing Practices
In the 1990s and early 2000s, standard protocol required primary care clinicians to treat
non-cancer persistent pain with short and long-acting prescription opiates (Dineen & DuBois,
2016). In the 1990s, United States pharmaceutical companies assured primary care clinicians that
using opioids to treat pain would not cause dependency (Abuse, 2020). In 1995, the American
Pain Society began describing patient-reported pain as the ‘fifth vital sign’ (Jones et al., 2018).
They strongly encouraged pain screening at every visit and the use of opiates when pain was
reported (2018). Over the next few years, this viewpoint was supported by various organizations
adopting these principles of less regulatory scrutiny over opioid prescriptions, such as Veterans
Health Administrative, Joint Commission (JC), Institute of Medicine, the Federation of State
Medical Boards, and the Federal Drug Enforcement Agency (FDEA). Medical clinicians were
mandated by the JC to treat pain if it was reported. Federal regulation of medical facilities
“mandated” these clinicians to prescribe opiates to those reporting persistent pain in order to
maintain funding (Jones et al., 2018, “Brief Timeline” section). Medical clinicians were at risk
for board complaints and even litigation by people with persistent pain if they did not prescribe
opiates when pain was reported (Tucker, 2004). Pharmaceutical companies began strong
marketing campaigns directly toward people with persistent pain and medical clinicians. This
marketing was aimed at convincing both medical clinicians and people with persistent pain that
opiates were an effective and non-addictive way to manage their pain (Weschler, 2013). As one
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author put it: “The culture change, driven by intent to ensure access to pain relief, had opened the
floodgates to the current opioid climate” (Jones et al., 2018, “Brief Timeline” section). This trend
would later be referred to as the beginning of the opioid epidemic or crisis as it was characterized
by the beginning of three distinct waves of opioid overdose deaths (Planalp et al., 2019).
Opioid Use Disorder
A cycle of dose escalation quickly emerged for patients who were prescribed opioids.
This escalation contributed to the iatrogenic effects of opioids, or the negative effect of a medical
intervention that was intended to help or treat the patient. In the case of opioids, the chronic use
often led to increased tolerance, dependence, withdrawal symptoms, cravings, and opioid
seeking behavior. Thus, a maladaptive cycle was reinforced: A patient reports some level of
pain, they are prescribed a heavily addictive medication (opioids), and when that pain is still
reported, they are prescribed more and more until the amount of opioids potentially put them at
risk for respiratory depression. As doses of opioids increased so did the other risks associated
with chronic opioid use: mortality, overdose morbidity, serious adverse side effects,
dependence/addiction, lifelong disability, and loss of family/community (Hiscott, 2014). This
cycle of prescribing practices ultimately contributed to a rapid increase of patients experiencing
an opioid dependence and a subsequent diagnosis of an Opioid Use Disorder (OUD)
characterized by brief relief in pain, tolerance, and significant time and effort spent obtaining
more opioids.
Response to Opioid Use Disorder
As described in the previous section, high doses of opioids not only lead to addiction but
also lose their effectiveness as the patient develops tolerance for the medication. Due to concerns
about addiction and lack of efficacy, many providers opted for reducing the dose of the opioid or

PSYCHOLOGICAL FACTORS FOR OPIOID USE DISORDER

3

tapering patients off opioids completely. Previously amidst the opioid crisis, providers had even
attempted to cut patients’ opiates completely without tapering which led to adverse outcomes. A
precipitant withdrawal of the medication often caused trauma and rupture in the provider/patient
relationship, anxiety around availability of treatment for pain, stigma for patients with OUD,
animosity, depression and in some cases led to suicide (Rothstein, 2017). This historic tension
between provider and patient has led to continued mistrust and lasting implications for future
treatment modalities around persistent pain.
Current Status of Opioid Use
From 2000 to 2017, rates of overdose in the United States from opioids increased
exponentially, from 1.0 to 4.4 per 100,000 people (Planalp et al., 2019). The specific cause of the
high overdose rates were unclear, which obscured accountability and prioritization of
interventions. Early data tracking did not identify the source of the opioids (prescriptions or
illicit substances) leading to the overdose, but more recently, researchers have attempted to
differentiate the sourcing (Planalp et al., 2019). Epidemiologists found that prescription opioid
overdose deaths experienced no growth from 2016 to 2017, suggesting progress in limiting
opioid prescriptions has reduced the impact of one cause of the opioid crisis. However, opioid
overdose deaths from illicit opioids have increased from 6.2 to 9.0 per 100,000 people between
2016 and 2017. These numbers reveal that while the efforts to curtail the prescription opioid
epidemic are affecting outcome, patients with OUD may have simply shifted to use of illicit
opioids. The Center for Disease Control (CDC) recently broadly reported drug overdose deaths
decreased 4% from 2017 to 2018, showing a downward trend. However, it remains the leading
cause of injury-related death in the US with almost 70% involving a prescription or illicit opioid
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(Centers for Disease Control and prevention, 2020). With this in mind, there is increased need to
continue to respond to the use of opiates across both prescriptive and illicit use.
Turning of the Tides
While not every patient on chronic opioids has a diagnosis of OUD, the risks often
outweigh the benefits and tapering can prove ineffective. Due to this, safer treatment options for
helping patients reduce or even eliminate their use of opioids have been developed. One
particularly efficacious treatment option became available with the introduction of Medication
Assisted Treatment (MAT). In 2000, the Center for Substance Abuse and Mental Health Services
Administration (SAMHSA) implemented the Drug Addiction Treatment Act of 2000 (DATA
2000), which allowed physicians to obtain a waiver (X-waiver or DATA waiver) to prescribe
schedule III, IV, and V medications (drugs which contain small amounts of narcotic and nonnarcotic drugs, anti-anxiety drugs, tranquilizers, sedatives, stimulants, and non-narcotic
analgesics), commonly referred to as MAT.
MAT is a combination of medications that target the brain (FDA approved: methadone,
buprenorphine, and naltrexone), and psychosocial interventions such as counseling and skill
development. The premise of MAT is to safely treat dependence on opioids, while reducing the
risks of overdose and chemical dependency. Buprenorphine (Suboxone) is a safe drug that
relieves cravings, pain, and is less likely to result in an overdose (Rothstein, 2017). MAT is
effective because it does not reinforce the cycle of chemical dependency; however, it does
continue a physical dependence on medication as opposed to a safe taper plan. Obtaining a MAT
waiver was possible for physicians, advanced practice registered nurses (NP, CNM, CNS, and
CRNA), and physician assistants. These medical professionals comprise the traditional primary
care team who would be able to provide this service outside of a specific MAT or pain clinic. In
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order to obtain an x-waiver, physicians must complete an eight-hour training and submit an
application form to SAMHSA Center for Substance Abuse Treatment (CSAT). Upon approval,
physicians will be allowed to treat 30 patients with MAT. Advanced practice nurses and
physician assistants are required to go through the same process but with 24 hours of training
required (Substance Abuse, 2020).
Initially, providers with a waiver could only prescribe the medication regime to 30
patients. In 2006, the Reauthorization Act allowed for providers with a waiver to treat up to 100
patients. In 2016, the FDA updated their public policies regarding the use of opioids, access to
treatment for chemical dependency to opioids, and numerous changes in the certification and
production of opioids that would be approved. In 2017, the Joint Commission (JC) released new
standards that focuses on “appropriate and effective” management of pain that included the
consideration of psychosocial risks, goal setting with patients, better monitoring of opioid usage,
and encouragement to seek out non-pharmaceutical options (Jones et al., 2018, “Reaction”
section).
Current Status of MAT Use
Since the implementation of MAT, the use of buprenorphine has shown to be extremely
successful in treating OUD (Knudsen et al, 2011); however, the requirements for a prescriber to
have an X-waiver has limited the accessibility of MAT. Data in 2020 shows that fewer than 5%
of eligible prescribers had a waiver to prescribe MAT. Overall, data from 2016 shows that only
10% of Americans in need of MAT have access to it. Americans specifically living in rural areas
have increased mortality rates for opioid overdose (Andrilla et al., 2019) and yet they are the
least likely to have access to a MAT prescriber. Recent studies have begun to analyze the
barriers to MAT exploring why more prescribers are not seeking a waiver/prescribing with a
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waiver to provide a research-based effective protocol for their patients with OUD (Knudsen et al,
2011; Logan et al., 2021).
Potential Barriers to Care
What are the causes for these barriers in accessibility and apparent reluctance to apply for
the X waiver? Some of the potential logistical barriers to prescribing MAT were previously
identified including the tedious and time-consuming process to obtain an X-waiver. In addition
to the provider’s training, their medical and support staff require extra training to provide the
services according to the detailed protocol, (Knudsen et al, 2011; Lowenstein et al., 2019).
Current research is investigating the logistical barriers for primary care providers to become
MAT prescribers (Knudsen et al, 2011; Logan et al., 2021). In an attempt to reduce barriers,
legislative efforts in 2021 sought to minimize the burden primary care providers experienced in
attaining a waiver and prescribing MAT by allowing an exemption from the 8 hours of training
for any physicians who were DEA registered. Unfortunately, this effort was rescinded days later
when the presidential office changed leadership and the DATA 2000 requirements were reestablished (Logan et al., 2021). The desire to provide this life-saving treatment led to the
suggestion of removing the barrier of an X-waiver requirement altogether in an effort to increase
provider engagement in MAT (Duncan et al., 2020).
Through surveys exploring the issue of provider reluctance, a few psychological themes
have surfaced such as providers endorsing a lack of confidence in themselves to prescribe and
treat OUD with MAT (Heesacker, 2019). Research by Kirane et al. (2019) assessed clinicians’
attitudes toward treating opioid use disorder with MAT and found that while additional training
on buprenorphine positively impacted attitudes and confidence, engagement in MAT remained
limited. Of the sample (313 providers), only 19% of providers reported feeling confident in
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treating opioid use disorders (Kirane et al., 2019). These results reflect the qualitative responses
from Heesacker’s (2019) survey from Jackson County, Oregon. Prescribers reported not feeling
confident in using MAT, although the contributors to the reported lack of confidence was
unclear; did the prescriber lack confidence in themselves, the patients, their system, or the MAT
protocol?
Another psychological construct representing either a barrier or a facilitator to healthcare
workers is compassion/compassion fatigue. Compassion is described as a multi-faceted and
sometimes vague concept in the literature. Compassion can facilitate care as it involves acting
proactively on virtues, seeking to understand, empathy, and action (Sinclair et al., 2016).
However, compassion fatigue can occur as an overextension of this caregiving role. Compassion
fatigue is described in nursing literature by Joinson (1992) as “disengagement, feelings of
helplessness, anger and apathy among other symptoms.” Figly (1995, 2002) described
compassion fatigue similarly, but broadens the concept by highlighting the relationship between
compassion fatigue and vicarious trauma. MAT providers are often working with patient
populations having multiple co-occurring medical and mental health conditions including
complex trauma, which not only increases the complexity of patient care, but may leave them
vulnerable to experiencing vicarious trauma.
Prior research exploring psychological constructs looked at the provider’s personality
characteristics as a potential protective or risk factor for working in the medical field. For
example, research examining personality factors using the Big Five model of personality
(Openness, Conscientiousness, Extraversion, Agreeableness and Neuroticism) suggested that
some personality factors may provide a protective role for providers implementing MAT and
engaging in this work. Specifically, medical professionals scores on the personality factors of
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“extraversion,” “agreeableness,” and “conscientiousness” were shown to be a protective factor
against experiencing posttraumatic stress symptoms in one study (Chung et al., 2007), while
clinicians with higher “neuroticism” were more vulnerable to experiencing posttraumatic stress
(Campbell-Sills et al., 2006). Another study found that providers having higher scores in the
personality factor representing “agreeableness” were more likely to experience burnout.
(O’Mahony et al., 2018). The above studies didn’t find a relationship between the “openness”
factor, which indicates how open-minded a person is, or how likely they are to enjoy learning
new things and the likelihood to experience post-traumatic stress or burnout.
Current Research Purpose
While current research has investigated the barriers primary care providers face
becoming MAT prescribers, there is little research on the factors impacting prescriber utilization
of MAT. The aim of this exploratory study is to identify common factors among prescribers
using the X-waiver in their patient care. Our goal was to understand the personal and
professional variables associated with the use of the X-Waiver, including the factors that are
negatively correlated with utilization. This research explored factors of compassion/compassion
fatigue, burnout, secondary traumatic stress, and the differentiation of confidence (in self, MAT
program, healthcare system, and the patient). Additional factors such as personal connection to
OUD, time spent prescribing/working with OUD, perceived support/risk, and the relationship
between personality and willingness to use their X-waiver were explored.
Hypotheses
•

H1(a & b): It was predicted that higher compassion and higher personal connection to
OUD would be positively correlated with use of their X-waiver (based upon number of
patients treated).
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H2 (a): It was predicted that high levels of burnout would be correlated the number of
patients treated (with providers experiencing burnout treating fewer number of patients).

•

H2 (b) The first prediction was that confidence in MAT would be correlated with number
of patients treated (with providers experiencing high confidence in MAT treating more
patients). The second prediction was that confidence in MAT would be negatively
correlated with burnout (with providers experiencing high confidence in MAT
experiencing less burnout.)

Exploratory Analyses
•

EA1: Are there differences across groups (those prescribing vs. not prescribing) in the
ProQOL Compassion Satisfaction, Burnout, or Secondary Trauma Stress scales?

•

EA2: Are there difference across groups in the personality characteristics of Openness,
Continuousness, Extraversion, Agreeableness, or Neuroticism scales?

•

EA3: Are there any patterns within or between groups in the extended themes:
confidence, personal connection to OUD, barriers, additional training desires, and
gratifying factors of this work.
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Chapter 2
Methods
Participants
Study 1. The first study consisted of two volunteer physicians that currently have an Xwaiver from a local hospital. Participants piloted the survey and concluded no additional
measures or questions should be included. Given this result, these participants were included in
the group for Study two.
Study 2. The second study was initially designed to include one group of providers with
an X-waiver, but due to lack of responses, we added a second group aimed at providers without
an X-waiver in hopes of attaining a matched sample. The second group was given the same
survey but without questions directly related to the X-waiver (such as number of patients treated
with X-waiver and confidence in Medication Assisted Treatment (MAT) questions. Both groups
included participants who were selected through a snowball sample. Due to the snowball style of
sampling for the second group, some participants completed the survey with an X-waiver; this
set of participants will be called Group 3. All participants were provided an informed consent
prior to involvement in this study. This study was approved by the Human Subjects Review
Committee (HSRC) at George Fox University prior to data collection (IRB #2202001).
Group 1. There were 11 participants who completed the survey for Group 1. All
participants in Group 1 carried an X-waiver. The typical respondent was white (100%), male
(72.7%), physician (81.8%), working in a primary care clinic (63.6 %) in a role as a physician
(63.6%), and in a rural setting (45.2 %). On average, the participants were 44 years of age (SD =
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8.08), with 10 years of work in their profession (SD = 5.61), with their waiver for 6 years (SD =
3.46).
Group 2. There were four participants without an X-waiver who responded to the second
survey. The typical respondent was white (75%), female (100%), a nurse practitioner (75%),
working in primary care (100%), in a leadership role (75%), in a suburban setting (50%). On
average, the participants were 44 years of age (SD = 5.83), with 11 years in the profession (SD =
8.72).
Group 3. Three participants responded to the second survey with an X-waiver. The
typical respondent was white (66.7%), male (100%), a physician (66.7%), working in primary
care (66.7%) in a leadership role (66.7%) in a suburban setting (66.7%). On average, the
participants were 38 years of age (SD = 5.86) with nine years in the profession (SD = 6.00). The
question regarding the number of years with an X-waiver was not included in the second survey
administration. Information was not gathered on years with the X-waiver due to response
difficulties mentioned above
Materials
A demographics questionnaire (see appendix C), as well as the Professional Quality of
Life Scale (ProQOL version 5; Appendix D), The Big 5 Inventory-10 (BFI-10; Appendix E) and
additional questions developed to explore Extended Themes (Appendix F, G, and H).
Professional Quality of Life Scale
The Professional Quality of Life Scale (ProQOL; Stamm, 2010) is a 30-item
questionnaire scored on a 5-point Likert scale with response options from never to very often.
The ProQOL incorporates two aspects of responses: the positive (compassion satisfaction) and
the negative (compassion fatigue). Compassion fatigue further breaks down into burnout or
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secondary traumatic stress. The measure has good construct validity with over 200 published
papers. The average score for compassion satisfaction is 50, with an internal validity (Cronbach
alpha) of .88. Scores on this scale below 40 reflect dissatisfaction with participants' job. The
average score for burnout is 50, with an internal validity (Cronbach alpha) of .75. Scores below
18 reflect a positive feeling of being effective at work, while scores above 57 reflect feelings of
being ineffective at work. The average score for secondary traumatic stress is 50, with internal
validity (Cronbach alpha) of .81. Scores above 57 reflect the possibility of feeling frightened at
work (Stamm, 2010).
The Big 5 Inventory-10
The Big 5 Inventory-10 (BFI) is a 10-item scale measuring adapted from the 44-item Big
Five Inventory (John et al., 1991). The BFI-10 accounts for 70% of the variance of the full scales
and was created to be used in settings where time is limited. The BFI-10 measures the Big Five
personality traits extraversion, agreeableness, conscientiousness, emotional stability, and
openness on a 5-point Likert scale ranging from Disagree Strongly to Agree Strongly. The BFI
demonstrates acceptable test-retest reliability for neuroticism (.74), extraversion (.84), openness
(.72), compatibility (.58), and consciousness (.77) Part-whole correlations with the BFI-44
scales, structural validity, convergent validity with other personality inventories and external
validity using peer ratings were demonstrated for the BFI-10 (Rammstedt & John, 2007).
Extended Themes and Open-Ended Questionnaire
An additional subset of questions (Appendix F) not related to an established measure was
also utilized to explore possible themes. The first theme explored providers perceived confidence
levels. Questions explored participants' confidence in their professional self, the MAT program,
their patients, and the healthcare system. There were 4 questions on a 5-point Likert scale
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ranging from very untrue of me to very true of me. The participants were told to expect to spend
3-5 minutes answering these questions. The second theme (Appendix G) explored participants'
personal connection to themselves or to another person who has/is dealing with Opioid Use
Disorder (OUD). These four questions were on a dichotomous scale and explored the nature of
the relationship (self, friend, relative, colleague, etc.). The third theme (Appendix H) focused on
the subjective experience of providers working with MAT including sense of barriers or
challenges, any additional training they perceived would be helpful, and what the providers
found gratifying in this work. The participants were told to expect to spend 7-10 minutes
answering the entire survey.
Procedure
Study 1. This study functioned as a pilot study with 2-3 participants. Participants were
asked to sign an informed consent. They were given the survey’s followed by open-ended
questions about their personal experience working within the opioid crisis and if there were any
other factors, they felt impacted their ability to treat OUD.
Study 2. Participants in Study 2 were asked to sign an informed consent and then the
survey was administered electronically. Data were analyzed using SPSS statistical package.
Data Analysis
Study 1. The data from Study 1 was used to determine if additional information needed
to be gathered from Study 2 participants. The survey data from Study 1 was used in conjunction
with Study 2.
Study 2. The data from Study 2 were analyzed using a Pearson product moment
correlation to identify positively and negatively correlated factors associated with MAT use. A
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regression analysis was used to determine the relative strength of the factors in predicting MAT
use. All data analysis is descriptive in nature.
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Chapter 3
Results

As described in Chapter 2, the initial study was meant to explore common themes among
providers with an X-waiver engaging in work with patients with Opioid Use Disorder (OUD).
However, due to a lack of responses from participants (n = 11 on the first administration), we
sought to attain a matched sample of providers without an X-waiver. Unfortunately, we also had
a very limited response to the request, which will be further explored in the limitations section of
Chapter 4. In total, there were three separate groups; Group 1 (n = 11) consisted of X-waivered
physicians, Group 2 (n = 4) consisted of non-waivered nurse practitioners, and Group 3 (n = 3)
consisted of X-waivered physicians working in leadership positions.
Hypothesis 1 Results
Hypothesis 1a of this study predicted that higher levels of compassion satisfaction
(ProQOL; Compassion Satisfaction Scale) would be correlated with a higher number of patients
treated in group one only. Results failed to show statistically significant relationships between
compassion satisfaction or personal connection to number of patients treated (see Table 1),
therefore Hypothesis 1a was not supported.
Hypothesis 1b of this study predicted that personal connections (self, relative, friend, or
colleague) to OUD would be correlated with higher number of patients treated. Results showed
moderate effect size correlations between number of patients treated and connections to
colleagues (r = -.420), connections to relatives (r = -.301) and connection to friends (r = -.32)
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respectively (items were reversed scored). The effect sizes suggest that if the study had a larger
number of participants, we may have reached statistical significance. Therefore, Hypothesis 1b
was partially supported.

Table 1
Results of Correlation for Hypothesis 1

Note. Pts treated for OUD were reverse scored.

Hypothesis 2 Results
Hypothesis 2a of this study predicted that higher levels of burnout (ProQOL; Burnout
Scale) would be correlated with treating fewer patients. Results failed to show statistically
significant relationships between burnout or confidence and the number of patients treated.
Hypothesis 2b had two predictions, first we predicted higher levels of confidence (self,
patient, clinic, or Medication Assisted Treatment program) would be correlated with higher
numbers of patients treated. This first prediction was not supported because there wasn’t a
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statistically significant correlation between confidence in MAT and number of patients treated
(see Table 2). The second prediction in Hypothesis 2b predicted burnout would be negatively
correlated with confidence in MAT. This second prediction was supported (see Table 2) because
there was a statistically significant large effect size correlations between burnout and confidence
in Medication Assisted Treatment (MAT) (r = .653, p = .003). Furthermore, there were three
large inter-correlations between confidence in provider, patient, and clinic ability suggesting
there may be mutual influence of confidence across these components.

Table 2
Results of Correlation for Hypothesis 2

Note. The burnout measure is a reverse-score measure.
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Exploratory Analysis
Professional Quality of Life Scale (ProQOL)
A nonparametric t-test (Kruskal-Wallis) was used to analyze ProQOL scores across all
three groups in compassion satisfaction, burnout, and secondary traumatic stress. There was
significance between groups in compassion satisfaction and burnout, but not secondary traumatic
stress. See Table 3.

Table 3
Results of Exploratory Analysis ProQOL
Ranks

CompassionSatisfaction

Burnout

SecondaryTraumaticStres
s

Group

N

Mean Rank

1

11

9.14

2

4

4.88

Total

15

1

11

6.86

2

4

11.13

Total

15

1

11

7.68

2

4

8.88

Total

15

A chi-square test of independence using the likelihood ratio was performed to examine
the significance between groups with compassion satisfaction X2 (2, N = 18) = 8.34, p = .02.
Group One (X-waivered physicians) were more likely to report higher compassion satisfaction.
The significance was also explored further between groups and burnout X2 (2, N = 18) = 6.11, p
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= .41. Results showed that Group One (X-waivered physicians) were less likely to experience
burnout than either of the other Groups. and Group Two (non-waivered nurse practitioners) were
more likely to report medium levels of burnout when compared to the other groups. See Table 4.

Table 4
Results of Kruskal-Wallis for ProQOL
Test Statisticsa,b

Kruskal-Wallis H
df
Asymp. Sig.

Compassion
Satisfaction
3.977

Burnout

SecondaryTraumaticStress

3.977

.600

1

1

1

.046

.046

.439

Note. a = Kruskal Wallis Test. b = Grouping Variable: Group.

The Big 5 Inventory-10 (BFI)
An ANOVA was used to explore the BFI-1- themes across groups. Group was the
independent variable with three levels, Group One (X-waivered physicians), Group Two (nonwaivered nurse practitioners), and Group Three (X-waivered physicians in leadership). The
dependent variables were openness, conscientiousness, extraversion, agreeableness, and
neuroticism. Due to the data not meeting necessary assumptions, a Huynh-Feldt correction was
used.
A one-way ANOVA revealed that there was a statistically significant difference in
openness between groups (F (2, 15) = [3.97], p = .04). Bonferroni test revealed that the mean
value of openness was significant different between Group 1 (X-waivered physicians) and Group
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2 (non-waivered nurse practitioners), with Group 1 significantly more Open than Group 2. See
Tables 5 and 6.

Table 5
Results of BFI-10 ANOVA

Exploratory Analysis: Extended Themes
Barriers Across All Groups. The third extended theme (Appendix H) focused on the
subjective experience of perceived barriers in the work with MAT and patients with OUD. These
questions were given to all participants. Across Group 1, results identified the following barriers
in reaching the X-waiver limit: clinic requiring more education on MAT, providers needing
further consult, and behavioral health support. Alternatively, Group 2 endorsed the following
barriers: lack of mentorship, stigma among clinic staff, and stigma among patients. Group 3
identified their primary barrier as needing more provider consultation. The lack of behavioral
health partnerships was the only barrier endorsed by members of all three groups.
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Table 6
Results of BFI-10 MANOVA

Qualitative Responses
An additional subset of qualitative questions (Appendix H) was asked of Group 1 (Xwaivered physicians) including provider’s interest in receiving additional relevant education, and
the factors they found gratifying when working with MAT and treating patients with OUD.
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Education
Of the 11 participants in Group 1, 55% participants (N = 6) reported wanting more
education on Motivational Interviewing strategies, 36% (N = 4) reported wanting further
education on the neurobiology and psychology of chronic pain, and 36% (N = 4) reported
wanting further education on risk stratification for patients with OUD.
Gratifying Factors
Most participants in Group 1 (9 of 11) explained what they found gratifying in their work
with MAT and patients with OUD. Participants cited the most gratifying part of their work is the
relationships they build with patients: “Witnessing” their success, satisfaction with treatment,
and growth with “compassion.” Additionally, providers reported they found it gratifying to
provide support for this population where support is normally limited. For example, participants
reported gratification in offering a “safe space,” providing “healthcare [patients] wouldn't be
getting without coming to our clinic for MAT,” and “advocating for someone with limited
support.”
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Chapter 4
Discussion
Contributions to Current Research
While Medication Assisted Treatment (MAT) has been shown to treat Opioid Use
Disorder (OUD) safely and effectively, patients and prescribers have reported barriers to
accessing MAT. Current research is investigating possible barriers for primary care providers
to prescribe MAT from a systemic lens (Knudsen et al, 2011; Logan et al., 2021). Despite
this, there has been little research exploring facilitators or factors among providers of MAT.
The purpose of this study was to conduct a preliminary investigation exploring common
themes amongst providers already utilizing MAT with a goal of using this knowledge to
mitigate barriers and emphasize facilitators that would encourage the practice of MAT.
Psychological factors that were explored through a survey included: compassion/compassion
fatigue, burnout, secondary traumatic stress, confidence (in self, MAT program, healthcare
system, and the patient), personal connection to OUD (self, relative, college, friend), number
of patients treated, time spent prescribing or working with OUD, and perceived support/risk.
Although not supported, Hypothesis 1a of this study predicted higher levels of
compassion satisfaction (ProQOL; Compassion Satisfaction Scale) would be correlated with
a higher number of patients treated in group one only. Across all groups, compassion
satisfaction was high and did not differ between groups. This high compassion scores may be
reflective of the high level of commitment and care for others inherent in healthcare
professionals.
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Hypothesis 1b was partially supported showing that a provider’s personal connection
to someone who had experienced an OUD was associated with their willingness to provide
MAT for a higher number of patients. If the survey had yielded a larger number of
participants, it is probable that a stronger association would have been found here. Personal
connection was broken down into four subcategories: self, colleague, relative, or friend that
has experienced OUD. The only subcategory that did not have an association with higher
amounts of patients treated with personal connection having experienced OUD as oneself.
The connection between providers having a colleague, friend, or relative having experienced
OUD explored whether personal relationships would impact the willingness to work with this
high-risk population within a difficult system (MAT). Personal connection was thought to
mitigate stigma and provide a higher level of willingness from providers due to relatability to
their patients based on their personal connection to a friend, colleague, or relative that has or
is experiencing OUD.
Hypothesis 2a of this study predicted that higher levels of burnout (ProQOL; Burnout
Scale) would be correlated with treating fewer patients. This hypothesis was not supported as
all groups showed low levels of burnout. This finding was surprising as there have been
numerous health care fields impacted with burnout when there are barriers to providing
efficacious care for patients. It is possible, that with a wider breadth of surveyed participants,
this finding would have been different. It is also possible that providers feel uncomfortable
sharing perceived barriers or difficulties in their work while there is a high need for the
treatment they provide.
Hypothesis 2b of this study had two predictions, first we predicted lower levels of
confidence (self, patient, clinic, or MAT program) would be correlated with lower numbers
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of patients treated and higher levels of burnout which was not supported. None of the
variables we assessed showed a relationship with the number of patients treated, which was a
surprise to the researchers. The second prediction, that there would be a relationship
prescriber’s confidence in MAT and lower reported levels of burnout was supported.
The study also showed a three-way large effect correlation with confidence in
provider ability and patient ability (r = .791), confidence in provider ability and clinic ability
(r=.814), and confidence in patient ability and clinic ability (r = .632). This result suggests
that confidence may have a contagion effect in that the provider’s confidence in their ability
and their confidence in the clinic’s ability to support the entire process may influence a
provider’s confidence in the patient’s ability to engage and vice versa.
When examining the results of the ProQOL across groups, results showed that Group
One (X-waivered physicians) were more likely to report higher compassion satisfaction.
Thus, this finding doesn’t indicate that providers utilizing MAT are at an increased risk for
compassion fatigue or burnout. Providers reporting higher levels of compassion satisfaction
feel pleasure in the work they do, and that they make meaningful contributions in their work
setting (Stamm, 2010). Group 1 likely reported higher levels as they are more involved in
MAT (providing life-saving treatment for a high-risk population). This group was also less
likely to experience burnout (feelings of hopelessness and difficulties) within their work.
This finding suggests that while treating patients with MAT has numerous barriers for
providers, the work is not increasing the likelihood of those providers burning out. In fact,
this study suggests providers engaging in use of MAT, when compared to those not treating
patients with MAT, are less likely to experience burnout.
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Results from the BFI-10 on openness revealed that Group 1 was significantly more
Open than Group 2. This finding is consistent with research showing that individuals with
higher levels of openness are more likely to be willing to learn and engage in new
experiences. Furthermore, people with higher scores in openness tend to be willing to take
more risks than those lower in openness (John et al., 1991). Providers that wish to treat OUD
patients with MAT must seek out additional training and federal certification, essentially,
they have to be open and flexible enough to learn a new system, medication, and how to
work with a highly stigmatized population.
All participants were given the option to answer an open-ended question exploring if
there were specific factors or parts of their work with patients with OUD that they find
gratifying. The overarching theme of relationships showed up in response to the aspect of
providers work that is most gratifying. Providing a “safe space,” additional care, and
destigmatized interactions in which providers “witnessed” significant change in patients.
This data supports values-driven work from healthcare professionals in a service-oriented
field.
Implications
The results of this study imply that personal connections, confidence in the systemic
support, and a personality factor of openness are likely to be protective factors for prescribers
of MAT. These factors may mitigate the difficulty of working with high-risk, stigmatized
populations. This study also implies that providers engaging in gratifying, values-driven
work may be more likely to contend with systemic barriers to provide this level of healthcare
that requires providers to seek additional training and qualification. Higher levels of
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satisfaction in work (providers feeling they can make a meaningful difference), equate to
lower levels of burnout and likely facilitate more engagement, and enjoyment in their work.
This study suggests there is a contagion effect of confidence which may occur when a
provider feels confident in their ability to treat patients, their clinic to support them, or their
patient’s ability to adhere to treatment, which may influence the provider’s willingness to
continue working with MAT. While rates of mortality from OUD remain high, this finding
suggests that one way to mitigate the burnout that can occur with a patient population having
both high acuity and high mortality is to build confidence through training, support, and buyin from patients.
Since the implementation of Medication Assisted Treatment (MAT) for treatment of
Opioid Use Disorder (OUD), rates of providers engaging in treating patients with MAT have
remained low. Although the possible systemic barrier of obtaining additional training and
certification (DATA 2000 waiver X-waiver), was reduced/ removed in 2021, the rates of
providers engaging in this work have remained low. This study does not support previous
research that indicated removing the barrier of an x-waiver would be sufficient to increase
providers willingness to engage in MAT. This study instead highlights the facilitators
(personal connection, confidence, and openness) that impact a provider’s willingness to use
MAT. Broadly speaking, this research showed insights into the personal factors of physicians
that influence MAT treatment which sheds light on the multitude of factors that must be
considered as we continue to respond to the historic opioid crisis.
Future Research
The lack of a geographically and demographically diverse population (including the
number of years in practice) of providers was a significant limitation in this study. Future
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research should have more representative sampling across rural, urban, and suburban areas.
In additional to setting, future research should broaden the demographic sample. Across all
three groups in this study, the average years spent in their profession was 10 years which
translates to the sampled providers entering their role as providers around 2010. Given the
beginning of the opioid crisis was around late 1990s, the healthcare system began to make
strides toward combatting it around 2000, and a reduction in opioid related deaths began in
2017, it is possible the sampled providers represent a skewed perspective of this topic (Jones
et al., 2018). Group One reported having their waiver for six years (SD = 3.46) and likely
only began this difficult work after the healthcare system reduced systemic barriers, provided
an effective treatment method, and began working to reduce damaging prescriptive practices.
While legislative efforts continue to move toward reducing the identified system
barrier of requiring a DATA 2000 X-waiver, future research should explore the impact of
additional barriers. Future research should not be limited to systemic barriers alone, but also
consider personality, and emotional investment in treating this population. A sample
comparison of providers with an X-waiver that are actively treating OUD patients with MAT
and providers with an X-waiver that are not treating OUD patients with MAT would better
capture psychosocial differences that could be used to mitigate barriers and increase
willingness from providers to engage in this work.
Limitations
The COVID-19 pandemic has posed a unique limitation to this study as healthcare
providers have been disproportionately impacted and were less available to complete a
research survey. This limitation resulted in a small sample of participants and an inability to
show statistical significance through the data collected. An additional limitation of the study

PSYCHOLOGICAL FACTORS FOR OPIOID USE DISORDER

29

is an inability to highlight nuances due to recent changes in waiver requirements. Since
providers previously reported the required training and application to obtain an X-waiver was
the most significant barrier, it is possible that with this change providers may have been less
motivated to complete a survey designed to look at barriers, possibly assuming that the
largest barrier was already taken away.
Summary
The current study sought to uncover trends in providers prescribing practices while
assessing possible factors involved including personality, compassion, compassion fatigue,
personal connection, and confidence factors. Results show that a prescriber’s personal
connections with people who had experienced an opioid use disorder was the most salient
variable associated with their willingness to prescribe MAT. This research also found that
positive association between a prescriber’s confidence in MAT and lower reported level of
burnout. This finding suggests that provider’s confidence in their team, the treatment and the
patient may not only be a protective factor against burnout, but allow the providers to
experience a gratifying relationship with patients.
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Appendix A
Informed Consent for Study 1

Informed Consent for Participation
I_____________________________________ understand that my participation in
this research project is voluntary and that I can withdraw from the project at any time without
penalty, up until the time that my responses are analyzed along with the other participants in
the group. I understand that I will be allowed to review transcripts of my interviews and will
be able to make corrections and clarifications as needed. I understand that this material will
be used solely for Courtney Spencer’s (investigator) Doctoral Dissertation and may be
published in a scholarly journal. I further understand all data will be kept confidential with
only the investigator of this research, a peer reviewer and a faculty advisor having access to
my name and identifying information. The only demographic information that will be
published will be my profession and county I work within. There will be no reference to my
name on any of the research material or public indication that I participated in this project. I
also understand that the investigator is required by State law to disclose any report of
suicidality, homicidally or abuse of a child or elder. I understand that I may contact Dr.
Mary Peterson at (503) 442-3237 if I have questions or concerns about my participation in, or
any part of, the research project.
By signing, I agree to participate in the research project, under the terms noted above.

Signature of participant:________________________ Date:________________

Signature of witness:___________________________ Date:________________
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Appendix B
Informed Consent for Study 2

Medication Assisted Treatment for Opioid Use Disorder
Principal Investigator: Courtney B. Spencer, MA. Doctoral Student, Clinical
Psychology, George Fox University, (813) 727-7541.
Study Purpose: The primary purpose of this study is to understand the factors
affecting provider use of MAT.
Study Procedures: Participation in this study will require approximately 12 minutes.
You will be asked to complete the online questionnaire that is linked to this consent form
(click on "I consent to participate" at the bottom of this page). Upon pressing the "submit"
button at the end of the questionnaire your responses will be submitted via the internet. This
website and our server are secure sites and your data are sent in encrypted form. However, if
you are concerned about submitting your data via the internet, you may print the survey and
mail in a paper copy. The mailing address is available at the end of the survey. Surveys
received by mail will be treated with the same protocol and confidentiality as surveys
received via the internet.
Risks: There are no known risks of the study procedures.
Confidentiality: All information obtained is strictly confidential. Only the Principal
Investigator (Courtney Spencer) and a faculty advisor will have access to the data.
Contact: If you have any questions or desire further information with respect to the
study, you may contact Mary Peterson by phone at (503) 442-3237 or by email at
mpeterso@georgefox.edu.
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Consent: I am aware that I have the right to ask questions and receive answers on any
questions related to this study. I am aware that I have the right to refuse to participate or may
withdraw from the study up until the point that my data is analyzed with the other group
participants. I understand that there are no foreseeable risks in my participation. I am aware
that, if the questionnaire is completed, it will be assumed that consent has been given. I am
also aware that by reading this cover page and by continuing on with the survey I am not
waiving any of my legal rights.
Please print this page to keep for your records and reference.
I have read and understood the contents of this form.
I consent to participate
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Personal and Professional Demographics

Age in years: _________

Ethnicity/Race:
❏ American Indian or Alaska Native
❏ Asian
❏ Black or African American
❏ Hispanic, Latino or Spanish Origin
❏ Native Hawaiian or Other Pacific Islander
Native American
❏ White
❏ Multi-racial
Member of another race, ethnicity, or origin, please specify: __________________
❏ Prefer not to answer.

Gender- with which of the following do you most strongly identify?:
❏ Female
❏ Male
❏ _________________
❏ Prefer not to answer
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Profession/qualifications:
Years in profession:
Years with x-waiver?
How many X-waiver patients are you cleared to see?
How many X-waiver patients do you see?
County in which you prescribe MAT?
Clinical setting in which you work?
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Appendix D
Professional Quality of Life Scale (ProQOL) version 5 (Stamm, 2010)

INSTRUCTIONS: When you [help] people you have direct contact with their lives.
As you may have found, your compassion for those you [help] can affect you in positive and
negative ways. Below are some questions about your experiences, both positive and negative,
as a [helper]. Consider each of the following questions about you and your current work
situation. Select the number that honestly reflects how frequently you experienced these
things in the last 30 days.

1 = Never 2 = Rarely 3 = Sometimes 4 = Often 5 = Very Often
__1. I am happy.
__2. I am preoccupied with more than one person I [help].
__3. I get satisfaction from being able to [help] people.
__4. I feel connected to others.
__5. I jump or am startled by unexpected sounds.
__6. I feel invigorated after working with those I [help].
__7. I find it difficult to separate my personal life from my life as a [helper].
__8. I am not as productive at work because I am losing sleep over traumatic
experiences of
a person I [help].
__9. I think that I might have been affected by the traumatic stress of those I [help].
__10. I feel trapped by my job as a [helper].
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__11. Because of my [helping], I have felt "on edge" about various things.
__12. I like my work as a [helper].
__13. I feel depressed because of the traumatic experiences of the people I [help].
__14. I feel as though I am experiencing the trauma of someone I have [helped].
__15. I have beliefs that sustain me.
__16. I am pleased with how I am able to keep up with [helping] techniques and
protocols.
__17. I am the person I always wanted to be.
__18. My work makes me feel satisfied.
__19. I feel worn out because of my work as a [helper].
__20. I have happy thoughts and feelings about those I [help] and how I could help
them.
__21. I feel overwhelmed because my case [work] load seems endless.
__22. I believe I can make a difference through my work.
__23. I avoid certain activities or situations because they remind me of frightening
experiences
of the people I [help].
__24. I am proud of what I can do to [help].
__25. As a result of my [helping], I have intrusive, frightening thoughts.
__26. I feel "bogged down" by the system.
__27. I have thoughts that I am a "success" as a [helper].
__28. I can't recall important parts of my work with trauma victims.
__29. I am a very caring person.

40
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__30. I am happy that I chose to do this work
Scoring the ProQOL
Compassion Satisfaction Scale:

3. ____
The sum of my Compassion
Satisfaction questions

So My
Score Equals

My Level of
Compassion

22 or less

43 or less

Low

Between 23 and 41

Around 50

Average

42 or more

57 or more

High

6. ____
12. ____
16. ____
18. ____
20. ____
22. ____
24. ____
27. ____
30. ____
Total : _____
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Burnout Scale:
The sum of my Burnout
questions

So My Score
Equals

My Level of
Burnout

22 or less

43 or less

Low

Between 23 and 41

Around 50

Average

42 or more

57 or more

High

*1. ____ = ____
*4. ____ = ____
8. ____
10. ____
*15. ____ = ____
*17. ____ = ____
19. ____
21. ____
26. ____
*29. ____ = ____
Reverse the scores for those that are starred.
0=0, 1=5, 2=4, 3=3, 4=2, 5=1
Total : _____
Secondary Trauma Scale:
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The sum of my Secondary
Traumatic Stress questions

So My
Score Equals

43

My Level of Secondary
Traumatic Stress

22 or less

43 or less

Low

Between 23 and 41

Around 50

Average

42 or more

57 or

High

more

2. ____
5. ____
7. ____
9. ____
11. ____
13. ____
14. ____
23. ____
25. ____
28. ____
Total : ___
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Appendix E
The Big Five Inventory-10 (BFI-10) (Rammstedt & John, 2007).

INSTRUCTIONS: How well do the following statements describe your personality?

I see myself
as someone who …

Disa

Disa

gree strongly gree a little

1. … is reserved

(
1)

2)

2. … is generally trusting
2)

3. … tends to be lazy
2)

4. … is relaxed, handles
2)

disagree

little

strongly

(

4)

3)

3)

4)

(

(

(

(

(

(

5)

(
4)

(

5)

(

(

(
5)

(

(

(
1)

ree

4)

3)

Ag

gree a

(

(
1)

stress well

3)

A

agree nor

(

(
1)

Neither

5)
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5. … has few artistic
interests

(
1)

2)

6. … is outgoing, sociable
2)

7. … tends to find fault
1)

2)

9. … gets nervous easily
2)

10. … has an active
2)

4)

3)

3)

4)

(

(

(

(

(

(

(

(

5)

(
4)

(

5)

(

(

(

5)

(

(

(
1)

4)

3)

(

5)

(

(

(
1)

4)

3)

(
5)

(

(

(
1)

4)

3)

2)

(

(

(

8. … does a thorough job

imagination

3)

(
1)

with others

(

5)

Scoring the BFI-10 scales (R = item is reverse-scored):
Extraversion: 1R, 5
Agreeableness: 2, 7R
Conscientiousness: 3R, 8
Neuroticism: 4R, 9
Openness to Experience: 5R, 10
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Appendix F
Confidence Questions

INSTRUCTIONS: How well do the following questions reflect your personal
experience?
1=Very Untrue of Me 2=Untrue of Me 3=Neutral 4=True of Me 5=Very True of
Me

__1. I feel confident in my ability to prescribe MAT for OUD?
__2. I feel confident in my patients to engage in their MAT treatment?
__3. I feel confident in my immediate system to support me in prescribing MAT?
__4. I feel confident in MAT as an effective and safe treatment for OUD?

PSYCHOLOGICAL FACTORS FOR OPIOID USE DISORDER
Appendix G
Personal Connection Questions

INSTRUCTIONS: Please take a moment to answer the following questions as they
relate to you.
1. I myself have experienced OUD or Opioid dependency?
Yes/No/Prefer Not to Answer
2. I have a relative who has experienced OUD or Opioid dependency?
Yes/No/Prefer Not to Answer
3. I have a friend who has experienced OUD or Opioid dependency?
Yes/No/Prefer Not to Answer
4. I have a colleague who has experienced OUD or Opioid dependency?
Yes/No/Prefer Not to Answer

47

PSYCHOLOGICAL FACTORS FOR OPIOID USE DISORDER

48

Appendix H
Subject Experience of Providers

INSTRUCTIONS: Please take a moment to answer the following questions as they
relate to you.
1. Are you currently experiencing any barriers or challenges related to using your Xwaiver? (check all that apply)
a.

There is not enough demand in my clinic/community

b.

Stigma among my clinic staff

c.

Stigma among my patients

d.

I have reached my X waiver limit

e.

Clinic staff need more education around MAT treatment

f.

Limited access to consultation or support to make clinical decisions with patients

g.

Limited partnership with behavioral health for referrals or consultation

h.

I don’t know enough about this topic

i.

I worry that if word gets out that I have a waiver, my patient panel will end up filled

primarily with patients with OUD.
j.

Other (please specify)
2. I would benefit from more education on: (check all that apply)

a.

Neurobiology and psychology of persistent pain

b.

When opioids are an appropriate treatment for persistent pain

c.

How to initiate a taper plan for opioid treatment

d.

when/how to cross-taper a patient from opioids to MAT

PSYCHOLOGICAL FACTORS FOR OPIOID USE DISORDER
e.

The difference between opioid dependence and OUD

f.

Risk stratification for patients with OUD

g.

Current evidence for effectiveness of MAT

h.

Motivational interviewing for clients with OUD

i.

Other (please specify)
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2. Are there any aspects there you find gratifying related to treating patients with MAT?
Please describe:_______________________________________________________

PSYCHOLOGICAL FACTORS FOR OPIOID USE DISORDER

50

Appendix I
Curriculum Vitae

COURTNEY B. SPENCER
APPIC ID: 1306050060
14555 SE 1ST ST., MCMINNVILLE OR 97128
(813) 727-7541
CSPENCER18@GEORGEFOX.EDU
Education
Psy.D. Doctoral Candidate in Clinical Psychology
August 2018-Present
Graduate School of Clinical Psychology (APA Accredited)
George Fox University Newberg, Oregon
• Track Specialty: Primary Care Psychology
• Health Resources and Services Administration (HRSA) Grant Student Recipient
o Engaged in specialized training with rural hospital patients with chemical
dependency, chronic pain, and other medical complexities.
o Participated in increased clinical hour requirements with hospital consultation,
primary care psychology and interprofessional trainings
• Academic chair: Mary Peterson, PhD, ABPP/CL
• Dissertation: “Psychological Factors that Interfere with Provider Use of Medication
Assisted Treatment for Opioid Use Disorder”
o Final Defense anticipated December 2021
• Expected graduation: May 2023.

M.A. Master of Arts, Clinical Psychology
Graduate School of Clinical Psychology (APA Accredited)
George Fox University Newberg, Oregon
• Academic chair: Mary Peterson, PhD
• Successful completion of SFE and CIAE competency exams
• Dissertation: Preliminary defense completed December 2020

May 2020

B.S.

May 2017

Bachelor of Science, Psychology
University of Maryland University College
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Completed while in the U.S, Navy

A.S.
•
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Associates of Science, General Studies
University of Maryland University College
Completed while in the U.S, Navy

August 2015

Clinical Experience
Practicum III: Behavioral Health Intern
August 2021-Present
Providence Medical Center, Sherwood, OR
• Supervisor: Annelise, Manns, PsyD and Kiersten Kelly, Doctoral Intern
• Population:
o Suburban medical clinic patients ranging from child to geriatric and varying in
sexual, gender, ability, and religious identities
• Provided risk assessments/safety plans, warm handoffs, intakes, interdisciplinary
consultation, psychotherapy, psychiatric evaluations, ADHD evaluations, MOCA
memory assessments, and psychodiagnostics test administration
• Provided short-term, trauma informed therapy from a Focused Action and Commitment
Therapy model for brief care
Behavioral Health Crisis Consultation Team Coordinator
June 2021-Present
Providence Hospital, Newberg, OR
Willamette Valley Medical Center, McMinnville, OR
• Supervisors: Luann Foster, PsyD
• Attended bi-weekly meetings to coordinate and represent team members concerns
• Attended weekly meetings with Yamhill County Assessment Team as the George Fox
Crisis Team representative to support coordination between teams
• Coordinated with the supervisors to create shift schedules, holiday schedules, manage
shift complications, and organize trainings for the team
Practicum II: Behavioral Health Intern
June 2020-June 2021
Providence Medical Center, Newberg, OR
• Supervisor: Jeri Turgesen, PsyD, ABPP, MSCP
• Population:
o Rural medical clinic patients ranging from child to geriatric and varying in sexual,
gender, ability, and religious identities
• Provided risk assessments/safety plans, warm handoffs, intakes, interdisciplinary
consultation, psychiatric evaluations, ADHD evaluations, MoCA memory assessments,
and psychodiagnostics test administration
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Provided short-term psychotherapy with 80% of patients, and long-term therapy with
20% of patients to include both in-person and virtual telehealth during the COVID-19
pandemic
Provided trauma informed therapy from a Focused Action and Commitment Therapy
model for brief care, and Person-Centered therapy
Engaged in clinical training rotation in family medicine providing on site consultation for
patients struggling with chemical dependency
Participated in group trainings with chemical dependency psychiatrist and individual
supervision
Completed five integrative assessment reports with patients ranging in diagnoses:
ADHD, PTSD, Persistent Depression, and a Language Disorder

Behavioral Health Crisis Consultation (BHCC) Team
May 2020-June 2021
Providence Hospital, Newberg, OR
Willamette Valley Medical Center, McMinnville, OR
• Supervisors: Luann Foster, PsyD; Mary Peterson, PhD, ABPP/CL; Bill Buhrow, PsyD
• Population:
o Community members accessing the rural hospital emergency department in
Newberg and McMinnville varying in age and their sexual, gender, and religious
identities
• Provided after-hour crisis intervention assessments for patients presenting with suicidal
ideation, homicidal ideation, or psychosis
• Collaborated inter-professionally with attending physicians, nursing staff, supervising
psychologists and county mental health services towards recommending inpatient
hospitalization, outpatient treatment (with community resources) and/or approved
discharge
• Managed cases, patients’ families, and triaged connection to inpatient hospital care
within interdisciplinary hospital settings
• Attended weekly supervision to staff cases and collaborate on diagnosis and treatment
plan

•
•
•
•

Practicum I: Behavioral Health Clinician
June 2019-June 2020
Willamette Valley Internal Medicine, McMinnville, Oregon
Supervisor: Dr. Luann Foster, PsyD
Population:
o Adults with chronic medical conditions from rural communities with low SES
Developed the position of BHC within the medical clinic providing co-located therapy
for a variety of mental and medical health conditions
Worked collaboratively with the medical staff to address barriers to care for patients for
long term chronic health conditions to help improve treatment adherence
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Provided telephone-based services to this population, due to COVID-19 limitations
Provided for long-term and short-term evidence-based therapy, including ACT,
interpersonal and person-centered therapy
Maintained clinical notes in patient’s electronic health records and engaged in
professional communication with other interdisciplinary team members for holistic care

Pre-Practicum: Supervised Psychotherapy
September 2018-April
George Fox University, Oregon
Supervisor: Glena Andrews, PhD, MSCP, ABPP & Christabel Leonce, PsyD
• Conducted Person-Centered Psychotherapy with two volunteer undergraduate students
who each received weekly individual one-hour sessions for ten weeks total
• Completed five prior training sessions with Doctor of Psychology students to build
foundational person-centered skills
Pre-Doctoral: Drug and Alcohol Prevention Advisor
January 2016-June 2018
U.S. Navy
Special Boat Team 20
Joint Expeditionary Base. Little Creek, Virginia
• Provided comprehensive alcohol and other drug abuse prevention and control policy and
procedures for all Navy military personnel at the command
• Promoted and trained Navy personnel on the “zero tolerance” policy on drug abuse and
discourage alcohol-related misconduct
• Assessed, built rapport, and coordinated care for all Navy personnel at the command that
volunteer for or ordered to attend treatment (inpatient and outpatient) for alcohol or
substance abuse and dependency
• Reported directly to the Commanding Officer and Executive Officer on all matters
covered under my responsibilities

•

•

•

Pre-Doctoral: President of CSADD
May 2013-May 2015
Coalition of Sailors Against Destructive Decisions
U.S. Navy
USS Mount Whitney. Gaeta, Italy
President of the USS Mount Whitney chapter of CSADD, leading 150 sailors in
command functions including monthly training self-help/team skills, and mentorship to
promote responsible decisions under direct supervisin of the Commanding Officer
Created monthly training or activities on the following topics: Sexual assault prevention
and response, suicide awareness, driving safety, off-duty recreation, domestic violence,
and more
Developed operational stress control activities during deployments to boost morale
including game nights, talent shows, and CSADD bingo
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Supervision, Teaching & Program Evaluation Experience
Supervisor to Practicum I Students
August 2021-Present
Graduate School of Clinical Psychology
George Fox University, Newberg, OR
Supervisor: Roger Bufford, PhD; Aundrea Paxton, PsyD
• Provided supervision to two doctoral students in their first clinical training sites under the
structure of the Supervision & Management PSYD course curriculum (taught by Dr.
Bufford, supervised by Dr. Paxton)
• Provided individual supervision, 2 hours/bi-weekly, and group supervision 1 hour/ biweekly around areas of personal and professional development: supporting theoretical
orientation development, offering evidence-based treatment recommendations, and
exploring their growth in the client/therapist relationship
• Provided formative and summative feedback to supervisees after clinical presentations in
alignment competency-based evaluation measures (supervised be Dr. Paxton)

•
•
•
•
•

Teaching Assistant (TA): Advanced Primary Care Psychology August 2021-Present
Graduate School of Clinical Psychology
George Fox University, Newberg, OR
Course Educator: Amber Nelson, PsyD
Fostered course curriculum for advanced training in Primary Care Behavioral Health
model including consultation and evaluation projects
Offered support and indirect supervision to students as they inquire about evidence-based
approaches for patients within the primary care settings
Conducted bi-weekly group clinical lab, lead discussion around topics covered in class or
patient cases
Managed logistics of course curriculum and announcements to enrolled students

Research Experience, Posters, & Related Experience

•

Research Vertical Team (RVT)
anuary 2019-Present
Graduate School of Clinical Psychology
George Fox University, Newberg, OR
Supervisor: Mary Peterson, PhD, ABPP/CL
Dissertation research: Psychological Factors that Interfere with Provider Use of
Medication Assisted Treatment for Opioid Use Disorder
o Pre-liminary defense: December 2020
o Expected final defense: December 2021
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Actively engaged in vertical research team comprised of 1st through 4th year doctoral
level trainees
Assisted in collaboration and development of dissertation and supplemental research
projects. Support includes direct feedback, collaborative support in developing areas of
interest, development of methods and completion of individual projects
Team-based areas of research interest include integrated care, opioid-use disorders and
MAT treatment providers, co-regulation and biofeedback, anti-stigma training around
HIV in health care settings, and trauma-informed resiliency training for pregnant mothers
Interprofessional Primary Care Institute (IPCI)
March 2019-Present
Director: Julie Oyemaja, PsyD, Oregon
Roles: Director of Research Assistant, and Student Outreach and Engagement
Conducted literature reviews across multiple disciplines and documenting a research
critique for all members of the institute to access
Managed and assisted in creating the IPCI website
Assisted with multiple trainings and intensives to include a major focus assisting Patti
Robinson, PhD with developing training videos, reviewing her publications, and
providing FACT training to fellow students on behalf of Dr. Robinson and IPCI
American Psychological Association Posters
Ramirez, S., Spencer, C., Drake, G., Wilbur, J., & Peterson, M. (2020, August).
Longitudinal Multi-disciplinary Chronic Pain Treatment in Rural Behavioral Health.
Poster presented at the American Psychological Association 2020 Virtual Conference
Hamilton, S., Spencer, C., Harberts, J., Reinhart, K., Peterson, M., & Logan, K. (2020,
August). Suicide Risk Assessment: An Evaluation of Graduate Students with the
Columbia-Suicide Severity Rating Scale (C-SSRS). Poster presented at the American
Psychological Association 2020 Virtual Conference
Primary Care Track & HRSA Grant Recipient
April 2019-Present
George Fox University, Newberg, Oregon
Supervisors: Kristie Knows His Gun, PsyD; Jeri Turgesen, PsyD; Mary Peterson, PhD,

ABPP
• Specific training to increase depth and breadth of behavioral health skills in a primary
care or general healthcare setting
• Completed the foundations of primary care & advanced primary care courses in the PsyD
program, as well as primary care elective courses such as neuropsychological assessment
and substance use treatment
• Trainings for Focused Acceptance and Commitment Therapy (FACT) in order to provide
brief primary care assessment and intervention that promotes radical change for patients
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Behavioral health intervention/treatment trainings and interprofessional primary care
trainings provided for HRSA primary care students
Received specific foundational training to treat and assess patients from any age across
the lifespan, presenting with a range of conditions from adjustment disorders to complex
medical conditions

Assessment
Completed five integrative assessment reports with patients (4 adults, 1 child) ranging in
diagnoses: ADHD, PTSD, Persistent Depression, and a Language Disorder
Have met program-wide competency and trained with the following assessment
materials:
WAIS-IV
16PF
Booklet
WISC-V
Conners-3
Categories
WIAT-III
MMSE
DKEFS
WMS-IV
MoCA
Grooved
MMPI-2
C-TONI
Pegboard
MMPI-2RF
CVLT-II
TPT
MMPI-A
CVLT-C
Rey-0sterrieth
MCMI-IV
TOMM
(RCFT)
PAI
WCST
Boston Naming
Certifications, Awards, & Affiliations

•
•

•

Trauma Certificate- George Fox University
December 2021
Courses: Trauma Work in Clinical Practice & Trauma Work Consultation Group
Professor: Kenneth Logan, PsyD
Formal training and course work on trauma-informed treatment processes, including
polyvagal theory and complex PTSD related diagnoses
Direct training and practice with advanced trauma treatment skills, including Stressresponse model, Primary nervous system functioning, Personality considerations for
treatment, and Process response evaluation of patients
Case conceptualization work with complex trauma patients, to consider essential
treatment aspects, such as: Client activation (emotions, memories, sensory experiences,
or cognitions), Avoidance responses (numbing, dissociation, suppression, denial, and
substance use), Emotional dysregulation (mood swings, depression episodes, acting out,
substance use, sudden dissociation events), and Relational disturbance (transference &
relationship history)
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At least twenty hours of supervised clinical practice at a program approved practicum site
treating clients for conditions caused by exposure to traumatic stress
Basic Life Support Provider- American Heart Association December 2018-Present
Successfully completed the cognitive and skills evaluations in accordance with the
curriculum of the American Heart Association Basic Life Support Program (CPR and
AED)
HRSA Scholarship Recipient
2020-Present
George Fox University, Newberg, OR
Recipient of competitive health services grant amidst engagement in Providence Medical
Group/ Primary Care Psychology Track
This project seeks to expand services to underserved, vulnerable populations through
simultaneous training for graduate psychology students in treatment for OUD/SUD and
establishment of tele behavioral health services (TBS)
American Psychological Association
Graduate Student Affiliate

2018-Present

Professional Trainings
May it be Well with Your Soul

November 2021

George Fox University
Dr. Brandy Liebscher& Pastor Liz Vaiz
Erotic Transcendence: Integrating Faith With
What's New In Sex Research

October 2021

George Fox University
Elisabeth Esmiol Wilson, PhD, LMFT
Telehealth Training for Behavioral Health Providers
George Fox University, HRSA Training
Dr. Jeff Sordahl

May 2021

Scaffolded Training in Culturally Specific Trauma-Informed Care
George Fox University, HRSA Training
Dr. Gil-Kashiwabara & Dr, Knows His Gun

May 2021
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OUD/MAT Clinical Work & Tools
George Fox University, HRSA Training
Dr. Brett Kaylor

May 2021

Native Culture and Individuals
George Fox University, HRSA Training
Pilar Peltier

May 2021

Gender Diversity/ Transgender Healthcare
George Fox University, Oregon
Cloe Ackerman, PsyD

March 2021

Removing Barriers to Integrated Behavioral Health in Primary Care: Research,
Practices & Implementation
March 2021
George Fox University, Newberg, Oregon via Zoom
Patti Robinson, PhD; Bhavesh Rajani, MD, MBA; Julie Oyemaja, PsyD
Embodiment/ Integration of Self
George Fox University, Newberg, Oregon via Zoom
Janelle Kwee, PhD
Complex PTSD: Advanced Case
Conceptualization, Assessment, and
Treatment Approaches in Trauma Populations
George Fox University, Newberg, Oregon
Jason Steward, PhD
Pediatric Cancer and Epilepsy
George Fox University, Newberg, Oregon via Zoom
Justin Lee, PhD

February 2021

November 2020

October 2020

Behavioral Health Clinician Essentials: BHC & FACT Training
August 2020
George Fox University, Newberg, Oregon via Zoom
Patti Robinson, PhD; Julie Oyemaja, PsyD; Bhavesh Rajani, MD, MBA; Jeri
Turgesen, PsyD, ABPP, MCP; Amber Nelson, PsyD; Sarah Rahcola, MD
FACT Training & Skills Workshop
George Fox University, Newberg, Oregon via Zoom
Patti Robinson, PhD; Kirk Strohsal, PhD

August 2020
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Interprofessional Solutions for High-Impact Chronic Pain
July 2020
George Fox University, Newberg, Oregon via Zoom
Bhavesh Rajani, MD, MBA; Paul Coelho, MD; Kathleen Gathercoal, PhD; Jeff
Houck, PhD, PT; Julie Oyemaja, PsyD
Child Adverse Events to Adults with Substance Use Problems
George Fox University, Newberg, Oregon
Amy Stober, PhD

February 2020

Interprofessional Solutions for Depression in Primary Care
January 2020
George Fox University, Newberg, Oregon
Bruce Arroll, MBChB, PhD; Patti Robinson, PhD; Florence Gerber, MBA; Bhavesh
Rajani, MD; Valorie Orton, RN, DNP; Jeri Turgesen, PsyD, ABPP, MCP; Celeste Jones,
PsyD, ABCCAP
Foundations of Focused Acceptance and
Commitment Therapy (FACT)
George Fox University, Newberg, Oregon
Kirk Strohsal, PhD
Intercultural Empathy & Cultural Intelligence
George Fox University, Newberg, Oregon
Cheryl Forster, PsyD

December 2019

October 2019

REACH Forgiveness
George Fox University, Newberg, Oregon
Everett Worthington, PhD

September 2019

Non-Violent Communication
George Fox University, Newberg, Oregon
Marshall Rosenberg, PhD

August 2019

Foundations of Relationships Therapy-The Gottman Model
George Fox University, Newberg, Oregon
Douglas Marlow, PhD
Suicidality Risk Assessment and Treatment
George Fox University, Newberg, Oregon
Luann Foster, PsyD

March 2019

February 2019
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Domestic Violence: A Science Based Approach
George Fox University, Newberg, Oregon
Patricia Warford, PsyD

February 2019

Opportunities in Forensic Psychology
George Fox University, Newberg, Oregon
Diomaris E. Safi, PsyD & Alexander Millkey, PsyD

February 2019

Working with Clients with Chronic Pain
George Fox University, Newberg, Oregon
Scott Pengally, PhD

October 2018

Spiritual Formation and the Life of Psychologist
George Fox University, Newberg, Oregon
Lisa McMinn, PhD; Mark McMinn, PhD, ABPP

September 2018

